Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced clearance from the U.S. Food and Drug Administration (FDA) of the Lithoplasty System for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

A new noninvasive skin closure device is more efficient and effective than other models when used during heart surgery, according to findings in a new study.

Balancing needs, utilization and cost while improving patient care are central to the mission of the interventional cardiology team at Emory Saint Joseph’s Hospital in Atlanta.

Infinix Elite’s Image Quality and Versatility Enables Paris Cardiology to Bring Better Care to Multi-State Patient Population.

Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB)  with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study. 

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

Good Samaritan Hospital in L.A. looks to its managers to preserve that margin by slashing supply costs without compromising clinical quality.